CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Alkermes [NASDAQ: ALKS]

Stephen Sheehan, Director of External Development and Manufacturing

Elevating CDMO Performance with Strategic Alignment

Stephen Sheehan

Stephen Sheehan

Manufacturing Collaboration Leader

Stephan Sheehan, director of external development at Alkermes, has built a career defined by innovation, adaptability and a relentless drive for excellence. With a Chemical Engineering degree from University College Dublin, he began his journey at Intel, where he mastered Six Sigma, root cause analysis and statistical process control. Sheehan then transitioned to Millipore, where he spearheaded the transfer of seven medical device production lines and optimised modelled membrane manufacturing processes, earning a Six Sigma Greenbelt. Since joining Alkermes in 2014, Sheehan has driven transformative change in pharmaceutical manufacturing. From pioneering the development of complex drug delivery candidates to managing CDMO partnerships for both small—and large-molecule projects, he has been instrumental in shaping Alkermes strategy and operations. His ability to navigate complex challenges and drive results positions him as a key figure in pharmaceutical innovation, shaping the future of the industry.


Recognising Sheehan’s visionary leadership and corporate fineness that has driven business success, this exclusive interview delves into his invaluable insights on transforming CDMO relationships from operational partnerships into strategic collaborations.


At a Glance:


• A tailored governance framework ensures each partnership aligns with evolving needs, fostering strategic collaboration and operational success.


• Root cause analysis and structured thinking drive effective resolutions without rigid reliance on formal frameworks.


• Weekly technical meetings focus on process development, while biweekly business meetings streamline financials and contracts, enhancing outcomes.


A Strategic Shift: Enhancing CDMO Performance


When I first started managing CDMOs, one of our biggest hurdles was working with a large molecule drug substance manufacturer. We faced communication breakdowns and inconsistencies in managing both the drug substance and drug product CDMOs for the same product. The absence of a standardised governance model only amplified these challenges.


“The key to effective problem-solving isn’t rigid frameworks—it’s disciplined, analytical thinking that uncovers root causes and drives actionable solutions”


Realising the need for a more strategic approach, we set out to develop a comprehensive governance framework. Our goal was to create a structure that would align business objectives with a clear, executable programme plan for our CDMOs. By focusing on building a best-in-class partnership—both strategic and operational—we aimed to streamline interactions and enhance efficiency. Nearly two years after implementing this model, it has become the cornerstone of our stronger, more effective CDMO collaborations.


The Three-Tier Approach


Our governance model elevates CDMO relationships from simple operational partnerships to strategic collaborations that drive lasting value. By aligning business, strategic and operational goals, we’ve created a three-tier model that guarantees seamless integration and mutual success.


At the top tier, ‘Business Direction,’ we define the strategic objectives for both Alkermes and the CDMO. Annual meetings help us align priorities, assess the CDMO’s evolving capabilities and identify new opportunities for growth. This ensures that as they continue to deliver high-quality results, we can explore new avenues for collaboration.


The middle tier, ‘Executional Oversight,’ turns these strategic objectives into actionable tactical plans, maintaining accountability throughout the execution process.


At the bottom tier, ‘Operational Delivery,’ the focus is on executing those tactical plans, ensuring every level of the partnership is aligned to deliver measurable, impactful results. This governance structure empowers both Alkermes and our CDMOs to work as true strategic partners, creating a future of collaboration, innovation and shared success.


The Governance Model Boosting CDMO Success


At the operational delivery level, we use a governance framework that is applied across all our CDMOs. However, each partnership is unique, so we tailor the operating model to meet the specific needs of the relationship. This model evolves based on lessons learned and the changing dynamics of the partnership.


One critical improvement we made was separating technical and business discussions. Initially, we combined these in technical meetings, which proved ineffective. Now, we hold weekly technical meetings focused solely on analytical development, process development, formulation and similar areas. Non-technical topics, such as contract reviews, invoice resolution, financials, team dynamics and risk mitigation, are addressed in biweekly business meetings. This separation makes sure technical teams can concentrate on their work without distractions, while business issues are handled efficiently. This dual-meeting structure has significantly improved technical and business outcomes, fostering stronger and more effective partnerships.


The Mindset of Analytical Problem-Solving


Six Sigma’s core principles of root cause analysis and analytical problem-solving remain central to my approach. For me, it’s less about adhering to a specific framework and more about embracing a disciplined mindset.


When tackling challenges, I prioritise a methodical, structured approach—breaking down problems to uncover root causes and devise effective solutions. This requires setting aside emotions and relationship dynamics to remain objective and focused on achieving the best outcome. Although I may not use Six Sigma tools directly, the analytical rigour it fosters continues to shape how I navigate and resolve complex issues.


Ask, Learn, Adapt: Strategies for Succeeding in a New Role


Transitioning from a technical field like process development to managing relationships and working with vendors can be a steep learning curve. One of the most valuable strategies is to ask questions and stay curious. I leaned heavily on colleagues with years of experience, setting up weekly meetings to discuss best practices and gain their insights.


Attending conferences and networking with peers also proved helpful in understanding industry standards and common challenges. It’s important to remember that most issues you encounter have likely been addressed before, so there’s no need to reinvent the wheel. However, while industry best practices are a great resource, they shouldn’t be copied and pasted directly into your organisation.


Instead, take the time to adapt them to the unique context of your situation to make them work effectively. By being curious, collaborative and adaptable, you can navigate the challenges of a new role with confidence.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

Life sciences companies need stronger governance models to keep technical execution, commercial priorities and long-term partnership goals aligned across outsourced manufacturing networks. Stephen Sheehan offers a practical framework for separating operational and business discussions, strengthening accountability and applying disciplined problem-solving to complex CDMO relationships.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/elevating-cdmo-performance-with-strategic-alignment-nwid-3613.html